An Antiretroviral Treatment Interruption(ATI) Study to Evaluate the Impact and Durability of AGT103-T to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy(ART) in Participants With Human Immunodeficiency Virus(HIV) Previously Treated With AGT103-T
Latest Information Update: 07 Dec 2022
At a glance
- Drugs AGT-103 (Primary)
- Indications HIV infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors American Gene Technologies International
Most Recent Events
- 30 Nov 2022 Phase amended from 1 to 4. Study design changed. Study involves unspecified masking.
- 16 Sep 2022 New trial record